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Purpose. To associate baseline patient characteristics and relapse across consecutive COG studies. Methods. We analyzed risk
factors for LESFT patients in three randomized COG trials. We evaluated age at enrollment, primary site, gender, tumor size,
and treatment (as randomized). We estimated event-free survival (EFS, Kaplan-Meier) and compared risk across groups (log-rank
test). Characteristics were assessed by proportional hazards regression with the characteristic of interest as the only component.
Confidence intervals (CI) for RR were derived. Factors related to outcome at level 0.05 were included in a multivariate regression
model. Results. Between 12/1988 and 8/2005, 1444 patients were enrolled and data current to 2001, 2004, or 2008 were used. Patients
were with a median age of 12 years (0–45), 55% male and 88% Caucasian. The 5-year EFS was 68.3% ± 1.3%. In univariate analysis
age, treatment, and tumor location were identified for inclusion in the multivariate model, and all remained significant (p < 0.01).
Since tumor size was not collected in the last study, the other two were reanalyzed. This model identified age, treatment, tumor
location, and tumor size as significant predictors. Conclusion. Age > 18 years, pelvic tumor, size > 8 cms, and chemotherapy without
ifosfamide/etoposide significantly predict worse outcome. AEWS0031 is NCT00006734, INT0091 and INT0054 designed before
1993 (unregistered).
1. Introduction
The 5-year event-free survival (EFS) for nonmetastatic Ewing
sarcoma patients has improved to 60–70% [1–6], but 2-
year survival for patients that relapse is 20–30% [7, 8].
Identifying factors predicting relapse may help develop new
strategies for those patients. Other studies have consistently
identified tumor location [3, 9–12] and age [9, 11–15] as EFS
predictors. Factors less consistently identified include lactic
dehydrogenase [9, 10, 13], histologic response [9, 13, 14, 16],
tumor volume [3, 6, 13, 14, 16, 17], tumor size [12, 18], and
surgical margins [19]. Histological response and surgical
margin accurately predict risk of recurrence but because they
can only be determined after chemotherapy and surgical
resection, they cannot help identify potential new strategies
for patients at the time of diagnosis.
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1444 new patients
(1988–2005)
INT-0091 (1998–1992)
530 patients enrolled
12 ineligible
120 metastatic
INT-0154 (P9354 1995–
1998)
492 patients enrolled
14 ineligible
478 patients available
AEWS0031 (2001–2005)
587 patients enrolled
18 ineligible
568 available 
200 with standard
arm (VDCA)
198
experimental
(VDCA + IE q 3
weeks over 48
weeks)
231 with VDC-IE
(q 3 weeks over 48
weeks)
247 with dose
intensive arm
(same doses
over 32 weeks)
284 with standard
timing (VDC-IE
q 3 weeks over
42 weeks)
284 with intensive
timing (VDC-IE
q 2 weeks)
Figure 1: CONSORT diagram for 1444 patients enrolled in three consecutive COG studies. The arms to which patients were randomized
are shown along with exclusion criteria and those patients who were thereby ineligible. CONSORT = Consolidated Standards of Reporting
Trials; COG = Children’s Oncology Group.
The Children’s Oncology Group (COG) and its prede-
cessors conducted three studies (1988–2005) for newly diag-
nosed localized Ewing sarcoma (ES) or peripheral primitive
neuroectodermal tumor (PNET) of bone [1, 2, 5] and/or soft
tissue. These studies included 1444 patients and used com-
mon chemotherapy agents. Most of the protocols’ eligibility
criteria overlapped and the schedule and evaluation methods
were similar. They carried forward “standard” therapies for
comparison.This series represents a group of patientswho are
homogeneous except for the patient/treatment factors exam-
ined in this analysis, reducing the likelihood that observed
associations are attributable to historical changes in patients
or evaluation methods.
We sought to pool the high-quality dataset represented by
those COG trials [1, 2, 5] to identify (1) demographic (i.e., age
and sex), (2) treatment-related (assigned chemotherapy), and
(3) tumor-related factors (tumor size and location) associated
with EFS.
2. Patients and Methods
2.1. Studies. We analysed selected factors at study enrolment
for 1444 patients treated in three COG studies: (1) INT-0091
[1]; (2) INT-0154 [2]; and (3) AEWS0031 [5] (Figure 1). The
INT-0091 study enrolled patients between 1988 and 1992 [1];
the INT-0154 enrolled patients between 1995 and 1998 [2];
while the most recent study (AEWS0031) enrolled patients
between 2001 and 2005 [5]. Details of the three studies have
been previously published [1, 2, 5].
Briefly, patients < 30 years of age with newly diagnosed,
histologically confirmed primary ES or PNET were eligi-
ble for enrolment in INT-0091 [1]. Eligible patients were
randomized to treatment with vincristine, doxorubicin, and
cyclophosphamide (VDC), with or without ifosfamide and
etoposide (IE). Although the study included patients with
metastatic disease, those patients are not considered in our
analysis. Patients < 30 years with newly diagnosed, histologi-
cally confirmed ES or peripheral PNET of bone or soft tissue
were eligible for enrolment in INT-0154 and were random-
ized to dose-intensified or standard therapy (Figure 1) [2].
The dose-intensified arm of the study administered the same
total doses of chemotherapy every 3 weeks over 32 rather
than 48 weeks. Patients < 50 years with newly diagnosed,
histologically confirmed ES or peripheral PNET of bone or
soft tissuewere eligible for enrollment inAEWS0031 andwere
randomized to receive the same chemotherapy doses every 2
weeks (dose-dense) or every 3 weeks (standard therapy) [5].
2.2. Treatment
2.2.1. Chemotherapy. The standard chemotherapy doses
included the following: VCD—vincristine 2mg/m2 (2mg
maximum dose), doxorubicin 75mg/m2/dose (either as a
single bolus, two daily boluses, or 48 h continuous infusion),
and cyclophosphamide 1200mg/m2, followed by mesna uro-
protection. Dactinomycin 1.25mg/m2/d was substituted for
doxorubicin when a total doxorubicin dose of 375mg/m2
was reached in INT-0091. Courses of IE included ifosfamide
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1800mg/m2/d for 5 days, givenwithmesna uroprotection and
etoposide 100mg/m2/d over the same 5 days.
2.2.2. Local Control. The studies prescribed local control
following 12 weeks of therapy, which in the first two studies
[1, 2] and in the control arm of the third study included four
cycles of chemotherapy but followed 6 cycles in the experi-
mental arm (every-2-week treatment) of the third study [5].
Although the choice of local control was left up to the treating
physician, all protocols provided guidelines [1, 2, 5]. The
protocols allowed surgery for tumors deemed resectable. For
radiotherapy alone, the initial tumor volume (soft-tissue and
osseous tumor extent) with a 3 cm margin was treated with
4500 cGy, followed by reduction in treatment volume to the
postchemotherapy, preradiotherapy tumor for 1080 cGymore
(total dose 5580 cGy). A smaller margin was allowed to avoid
radiation to the epiphysis. Patients with residual tumor after
surgery were irradiated using the dose-volume guidelines
for gross residual disease; for microscopic residual disease,
irradiation was limited to 4500 cGy to the original volume
with a 1 cm margin. No supplemental radiotherapy was
administered to patients achieving a complete resection of
the primary tumor with clear margins regardless of extent of
necrosis or tumor size. For patients with extraosseous tumors
and a complete response to induction chemotherapy, the
initial tumor volume plus a 2 cm margin received 4500 cGy
followed by a boost of 540 cGy with a 1 cmmargin (total dose
5040 cGy).
2.3. Statistical Methods. We defined EFS as the time from
study entry until the occurrence of an analytic event or
date of last contact, whichever came first. An analytic event
was defined as disease progression, diagnosis of second
malignant neoplasm (SMN), or patient death prior to the
development of disease progression or SMN. A patient who
had not experienced an event by the date of last follow-upwas
censored.
Exploratory analysis was complicated by the fact that
some data were not collected in all studies and even when
intended to be collected some data were missing. The major
sources and types of missing data were as follows: (1) INT-
0091 excluded patients with extraosseous ES from enroll-
ment; (2) in AEWS0031 tumor size was not collected; and (3)
tumor size was not reported for 266 participants in the other
two studies. We therefore excluded tumor size and soft-tissue
ES from our first multivariate model. Participants whose data
were truly missing (request for data present but not provided
by the institutional investigators) were also eliminated from
the analysis.
The distributions of EFS and overall survival were esti-
mated by the method of Kaplan and Meier [20]. Risk
of adverse event was compared across groups, defined by
treatment or prognostic factors using the log-rank test.
Comparisons involving the chemotherapy randomizations
were conducted with patients’ outcomes assigned to their
randomized treatment arm at enrollment (intent-to-treat
analyses). The prognostic significance and associated RR for
various patient characteristics measured at study entry were
assessed by a proportional hazards regression model with the
characteristic of interest as the only component. Confidence
intervals (CI) for RRs were derived from the proportional
hazards regression model [21]. In addition, a likelihood
ratio test was performed to confirm the homogeneity of
model parameters across studies. The likelihood ratio test
statistic was constructed by comparing the likelihood from
the stratified Cox regression model fitting common risk
coefficients stratified by study (assumes model parameters
are not different across strata) with the likelihood of the Cox
regression fitting study-specific risk coefficients.
Only potential prognostic factors measured at study
enrollment were assessed in the dataset. In particular, the
relationship between risks of an event and death and local
control modalities were not analyzed.The potential prognos-
tic factors considered included the following: (1) patient age
at enrollment; (2) site of primary tumor; and (3) patient sex.
Age at enrollment was categorized.
All the factors noted abovewere explored further to assess
their relative prognostic effects when considered jointly. To
determine whether tumor size had an impact on outcome
using COG-directed therapy, we performed a second mul-
tivariate analysis including only patients enrolled in INT-
0091 and INT-0154, where tumor size in two perpendicular
dimensions was requested but not required for eligibility.
This allowed us to determine whether tumor size was an
independent predictor of EFS using US treatment (in COG).
For this analysis, tumor size was categorized.
3. Results
A total of 1444 patients were enrolled in INT-0091, INT-0154,
and AEWS0031 between December 1988 and August 2005
(Figure 1). The INT-0091 trial opened in December 1988 and
closed in November 1992. Data current to August 2001 were
used for our analysis, which included 395 eligible patients.
The INT-0154 trial opened in March 1995 and closed in
September 1998. Data current to December 2006 were used
for our analysis, which included 477 eligible patients. The
AEWS0031 trial opened in May 2001 and closed in August
2005. Data current to March 2009 were used for our analysis,
which included 568 eligible patients. Baseline characteristics
included a median age of 12 years (range, 0–45), and 55% of
patients were male (see Table 1 for details).
The 5-year EFS for the 1444 patients enrolled in the
three studies was 68.3% ± 1.3% (Figure 2). The 5-year EFS
for INT-0091, INT-0054, and AEWS0031 was 61.5% ± 2.5%,
71% ± 2.1%, and 70% ± 2.6%, respectively.The risk for anEFS
event differed significantly across studies (𝑝 = 0.0071). This
is likely driven by the absence of IE in the control arm of INT-
0091, since INT-0154 and AEWS0031 have very similar EFS.
As seen in Table 2, the RRof an event using the intensively
timed treatment of AEWS0031 relative to the standard timing
is 0.75 (0.5–1.01) confirming that intensively timed therapy
reduced event risk compared to standard-dose-and-timing
IE or non-IE containing treatment across the studies. In this
pooled analysis, the confidence intervals cross 1 (𝑝 = 0.061)
and are just outside conventional statistical significance.
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Table 1: Characteristics of 1444 patients enrolled in COG studies.
Factor Study
INT-0091 INT-0154 (P9354) AEWS0031 Total
Number of patients 398 478 568 1444
Median age, years (range) 12 (0–28) 12 (0–30) 12 (0–45) 12 (0–45)
<9 years, 𝑛 (%) 121 (30) 148 (31) 162 (28) 431 (29.9)
9–18 years 227 (57) 265 (55) 339 (60) 831 (57.6)
>18 years 50 (13) 65 (14) 67 (12) 182 (12.6)
Sex, %
Men 57 55 54 55
Women 43 45 46 45
Primary sites, 𝑛 (%)
Appendicular 188 (47) 175 (36) 195 (34) 558 (39)
Thoracic 69 (17) 75 (16) 89 (16) 233 (16)
Pelvic 93 (23) 70 (15) 90 (16) 253 (18)
Other axial 48 (12) 57 (12) 75 (13) 180 (12)
Extraosseous — 94 (20) 119 (21) 213 (15)
Missing 0 (0) 7 (1.5) 0 (0) 7 (0.48)
Tumor size, 𝑛 (%)
<8 cm 155 (30) 141 (29.5) 0 (0) 296 (10)
9–12 cm 113 (28) 98 (21) 0 (0) 211 (15)
>13 cm 64 (16) 39 (8.2) 0 (0) 93 (7)
Not reported 66 (17) 200 (42) 568 (100) 834 (57.8)
COG = Children’s Oncology Group.
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Figure 2: EFS for 1444 patients enrolled in consecutive COG trials.
The 5-year EFS for the group was 68.32% ± 1.3%. EFS = event-free
survival; COG = Children’s Oncology Group.
Additionally, the RR of an event using the non-IE armof INT-
0091 relative to the standard timing arm of AEWS0031 is 1.5
(1.12–2). This confirms the inferiority of non-IE containing
regimens as the risk of an event is 50% higher in those
patients. The RRs are similar for patients in the standard
timing IE treatments.
Univariate analysis identified three variables for consid-
eration in assessing the relative values of prognostic factors
measured at study enrollment (Table 3): (1) patient age at
enrollment (≤9 years, 10–17 years, and≥18 years); (2) assigned
treatment (intensive-timing IE, standard timing IE, and non-
IE); and (3) tumor location (pelvis, nonpelvic bone).
Table 4 presents the results of the multivariate analysis
including the estimated risk coefficients and 95% confidence
intervals. Patient age at enrollment remains a significant
predictor of EFS, and patients ≥ 18 years have greater than
a twofold increased risk of an event (RR 2.14 (CI 1.59–2.87,
𝑝 = 0.000)) compared to patients ≤ 9 years.
Tumor location and assigned treatment also retain their
role as significant predictors of EFS in the presence of
one another. Patients with a pelvic tumor have a higher
event risk RR 1.34 (1.07–1.67) than patients with nonpelvic
tumors. Assigned treatment was also an important predictor
of outcome and patients treated with non-IE containing
treatment had an increased event risk RR 1.84 (1.33–2.53).
In our multivariate analysis, risk of event was unrelated to
patient sex. The estimates of the effects of age, tumor site,
and treatment did not differ significantly between trials (𝑝 =
0.2587).
We also evaluated whether tumor size and tumor location
were both predictive of outcome by performing a second
multivariate analysis including only patients treated in INT-
0091 and INT-0154. As shown in Table 5, age, tumor loca-
tion, non-IE treatment, and tumor size were all significant
predictors of EFS. In this analysis patients ≥ 18 years have
a twofold event risk compared to younger patients (RR 1.97
(1.33–2.93)). Patients treated with a non-IE regimen have
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Table 2: EFS risk by treatment arm relative to standard treatment in AEWS0031.
Treatment Hazard ratio Std. error 𝑍 𝑝 > 𝑧 Confidence intervals
AEWS0031-ST 1.00
AEWS0031-IT 0.7488 0.1157 −1.87 0.061 0.5532 1.0135
INT-0154-HD 0.8805 0.1339 −0.84 0.4020 0.6536 1.1861
INT-0154-SD 0.8034 0.1271 −1.38 0.1660 0.5891 1.0955
INT-0091-IE 0.9613 0.1527 −0.25 0.8040 0.7042 1.3123
INT-0091-Std. 1.5064 0.2212 2.79 0.0050 1.1296 2.0088
Table 3: Estimated risk coefficients on univariate analysis for 1444 patients treated in consecutive COG studies.
Factor Characteristic Relative risk 95% confidence interval 𝑝 value compared reference Global 𝑝 value
Age yrs. (ref. <9) 0.0000
10–17 1.34 1.08–1.66 0.0090
18+ 2.35 1.78–3.11 0.0000
Primary site (ref. pelvis) 0.0002
Nonpelvic tumor 0.70 0.52–0.93 0.0140
Extraosseous 0.52 0.37–0.72 0.0000
Gender (ref. male) 0.3404
Female 0.92 0.77–1.10 0.08
Treatment (ref. standard timing) 0.0002
Non-I/E 1.65 1.31–2.09 0.0000
Intensive timing 0.82 0.64–1.06 0.1260
Tumor size, cm (ref. <8) 0.0002
9–12 cm 1.26 0.96–1.65 0.0990
>13 cm 1.98 1.45–2.70 0.0000
Table 4: Estimated risk coefficients for multivariate analysis excluding extraosseous patients (𝑁 = 1231).
Factor Characteristic Relative risk 95% confidence interval 𝑝 value comparedto reference Global 𝑝 value
Age yrs. (ref. ≤9) 0.0000
10–17 1.24 0.98–1.55 0.070
18+ 2.14 1.59–2.87 0.000
Primary site (ref. nonpelvic) 0.0110
Pelvic tumor 1.34 1.07–1.67 0.009
Treatment (ref. intensive timing) 0.0001
Standard timing 1.13 0.86–1.48 0.384
Non-I/E 1.84 1.33–2.53 0.000
Table 5: Estimated risk coefficients for patients treated in INT-0091 and INT-0154 (P9354) [excluding patients in AEWS0031] (𝑁 = 716).
Factor Characteristic Relative risk 95% confidence interval 𝑝 value comparedreference Global 𝑝 value
Age yrs. (ref. ≤9) 0.0043
10–17 1.27 0.93–1.72 0.130
18+ 1.97 1.33–2.93 0.001
Primary site (ref. nonpelvic) 0.0173
Pelvic tumor 1.44 1.07–1.92 0.014
Treatment (ref. standard timing) 0.0019
Non-I/E 1.56 1.19–2.05 0.001
Tumor size, cms (ref. <8) 0.0005
9–12 cm 1.24 0.93–1.65 0.137
>13 cm 2.00 1.43–2.79 0.000
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a 56% higher event risk than those treated with IE regimens
(RR 1.56 (1.19–2.05)). Importantly, both pelvic tumor location
and tumor size are predictors of EFS in the presence of each
other. Patients with pelvic tumors have a 44% increased risk
of an event RR 1.44 (1.07–1.92) while patients with tumors >
13 cm have an event risk twofold higher than patients with
tumors < 8 cm RR 2.00 (1.43–2.79).
4. Discussion
Previous studies have identified tumor location [3, 9–12] and
age [9, 11–15] as consistent predictors of poor EFS. The two
large series (>500 patients) [11, 13] assessing factors pre-
dicting relapse were both based on the European treatment
approaches. The chemotherapy treatment and local control
approaches in Europe differ from those in the United States.
For instance, European investigators stratify patients based
on tumor size [16, 17] and consider histological response to be
the most important predictor of outcome [16, 22]. Therefore,
we thought it important to evaluate demographic, treatment,
and tumor characteristics for their impact on EFS using a
large dataset of US treated patients.
Our study had several limitations related to its retrospec-
tive nature, including the fact that some patient character-
istics were not missing at random. These included tumor
size (not collected in AEWS0031) and patients with soft-
tissue tumors (not included in INT-0091). We excluded these
factors from our first multivariate model rather than employ
methods to impute the missing information and adjust 𝑝
values and confidence intervals accordingly.We also excluded
any participants with missing data from our analysis. Our
second multivariate analysis included only patients in INT-
0091 and INT-0154 since tumor size was part of the data
collection.This reduced dataset represents individuals where
the initial data collection strategy included assessment of
maximum tumor dimension. We consider this approach
optimal for evaluating the relative importance of tumor size
and tumor location in our studies.
We were able to confirm the importance of age ≥ 18 years
as an independent predictor of worse EFS. Though older age
has been consistently identified as predicting higher event
rates in multiple series [9, 11, 13, 14], the age cutoff has varied
from 12 to 15 years among those studies. This variability
likely reflects the eligible patient population included in
these studies. Additionally, a small study reported that older
patients did as well as younger patients if treated with similar
therapy [23]. Our analysis indicates that in the context of US-
style therapy age ≥ 18 years is an important predictor of worse
EFS. Our conclusions are limited by the small number of
patients older than 25 years; therefore, continued enrollment
of patients≥ 18 years in randomized controlled trials will help
further characterize the optimal age cutoff for predicting EFS.
Tumor location also predicted increased event risk;
patients with pelvic primaries were particularly at high risk.
This finding agrees with other studies of ES [1, 2, 11, 12,
15, 24] and is consistently used as a stratification factor in
both European and North American studies. Determining
whether the treatment of patients with pelvic tumors is better
if they are treated with the combination of surgery and
radiotherapy is difficult since randomization for this subset
would not be feasible. European studies more frequently use
a combination of surgery and radiotherapy for such patients.
This strategy is one not frequently used in the United States,
and EFS is similar suggesting that both approaches may be
equivalent.
Assigned chemotherapy treatment was an important
predictor of EFS in our study. As expected from results
of our previous trials [1, 2], the EFS for patients treated
with high- and standard-dose IE did not differ, but patients
receiving non-IE containing therapy had a higher risk of
an event with RR 1.63 (1.29–2.06). The use of IE with VDC
has become part of the US standard treatment for patients
with ES [1, 2, 5]. Additionally, in our analysis the RR of an
event for patients treated with dose-dense therapy was 0.89
(0.67–1.16), consistent with a protective effect. However, this
result does not achieve conventional statistical significance.
The reference group (standard timing IE) is heterogeneous
in that it included patients treated with increased doses of
ifosfamide and cyclophosphamide. This is in contrast to the
results of the COG randomized trial, which confirmed the
importance of dose-dense therapy in improving EFS [5].This
phenomenon has been well documented in the literature
and supports the contention that randomized controlled
trials are the preferred method to evaluate the prognostic
significance of interventions, where control can be exercised
over factors that could confound the statistical comparison
[25].
We were able to document the importance of tumor size
in the context of tumor location in our second multivariate
analysis (limited to INT-0091 and INT-0154), which revealed
a twofold increased risk of an event for patients with tumors
larger than 13 cm (RR 2.00 (1.44–2.79)). On average, patient
risk appeared to increase with larger tumor size. The size of
our population limited our sensitivity to these more subtle
differences. Tumor size and/or volume have been identified
in a number of studies as significant predictor of event risk
[1, 3, 11–13, 16, 17] and have been incorporated into the current
Euro-Ewing protocol where patients with estimated tumor
volume greater than 200mL [16, 17] are considered at high
risk and are eligible for randomization to continuing standard
chemotherapy versus intensification with the use of stem-
cell transplant.The tumor cutoff of 200mL used in European
studies [13, 16, 17] is a smaller volume than the greater than
8 cm size used in North America (which corresponds to a
268mL spherical tumor) [1, 12].
In conclusion, this is the largest series of US treated ES
patients receiving a similar therapy backbone. We confirmed
that primary tumor site (in the pelvis) and age ≥ 18 years
are predictive of an increased event risk and should be
considered at the time of treatment assignment. Patients ≥
18 years and those with pelvic tumors might benefit from
new treatment strategies. For example, chemoradiotherapy
may allow resection for a larger number of pelvic tumors.
Larger tumor size is also a predictor of worse EFS and
should be included as a stratification factor in future US
trials.
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